Burden of invasive pneumococcal disease (IPD) over a 10-year period in Bogotá, Colombia

Invasive Pneumococcal Disease Characterization in Adults and Subgroups aged < 60 years and ≥ 60 years in Bogota, Colombia

“…Despite a major decrease in the overall rate of pneumococcal disease in children ( de Oliveira et al., 2016b ; Shioda et al., 2020 ; Carrasquilla et al., 2021 ; Severiche-Bueno et al., 2021 ), a replacement of vaccine serotypes to non-vaccine serotypes has been observed after the introduction of PCV for children ( Camacho Moreno et al., 2020 ; Agudelo et al., 2021 ). Unlike evidence available for children, indirect effects of childhood PCV vaccination on pneumococcal disease burden in adults are scarce in Latin America.…”

“…Unlike evidence available for children, indirect effects of childhood PCV vaccination on pneumococcal disease burden in adults are scarce in Latin America. Nevertheless, morbidity and mortality seem to remain high among adults ( Whitney and Toscano, 2021 ; Severiche-Bueno et al., 2021 ).…”

“…In Colombia, although bacterial meningitis is a notifiable disease, the surveillance of IPD is performed through a voluntary passive system. The isolates are collected from a national laboratory network and submitted to the National Institute of Health ( Instituto Nacional de Salud [INS]) for confirmation, serotyping and antimicrobial susceptibility ( Castañeda et al., 2009 ; INS, 2018 ; Severiche-Bueno et al., 2021 ). Moreover, a sentinel surveillance for bacterial pneumonia and meningitis in children under the age of five years was implemented in a tertiary pediatric hospital in Colombia ( Camacho-Moreno et al., 2021 ).…”

Related Factors to Streptococcus pneumoniae Invasive Infection and Clinical Manifestations: The Potential Role of Nasopharyngeal Microbiome

“…Invasive pneumococcal disease (IPD) refers to an infection confirmed by the isolation of S.pneumoniae from a normally sterile site (pneumonia, parapneumonic empyema, meningitis, bacteraemia/sepsis, peritonitis and arthritis) ( 4 ). Its incidence, despite its remarkable reduction since the introduction of pneumococcal conjugated vaccine (PCV), is still 10–20/100,000/year in developed countries and could be even higher in developing countries ( 5 – 11 ).…”

Safety and Immunogenicity of V114 in Preterm Infants: A Pooled Analysis of Four Phase Three Studies

“…In addition, disease due to certain serotypes, such as 3 and 19A, continues to persist, owing to either a lack of inclusion in the PCV being used [10-valent PCV (PCV10)] or low vaccine effectiveness ]. 13,[33][34][35][36][37] V114 (VAXNEUVANCE, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ) is a 15-valent PCV containing all 13 serotypes in PCV13 (Prevnar 13, Wyeth LLC, marketed by Pfizer, New York, NY) plus serotypes 22F and 33F, 2 epidemiologically important serotypes associated with a high degree of invasiveness and antimicrobial resistance. 35,[38][39][40][41][42][43][44] V114 is approved for use and recommended as part of the standard of care in individuals ≥6 weeks of age in the United States, the United Kingdom, European Union and Canada, 39,[45][46][47] and is currently being evaluated for pediatric use by other regulatory authorities.…”